Cox proportional hazard analysis of risk factors for severe (grade ≥3) CAR T-cell–associated organ-based toxicities
| . | HR (95% CI) . | |||||
|---|---|---|---|---|---|---|
| Cardiovascular . | Metabolic . | Hematologic . | Infection with source . | Neurologic . | Pulmonary . | |
| Age, ≥60 vs <60 y | 1.39 (0.37-5.24) | 1.43 (0.68-3.02) | 0.73 (0.37-1.45) | 0.78 (0.32-1.94) | 2.88 (0.62-13.3) | 1.75 (0.35-8.70) |
| CAR T-cell product, tisagenlecleucel vs axicabtagene ciloleucel | N/A* | 0.62 (0.27-1.44) | 0.46 (0.19-1.13) | 0.96 (0.35-2.64) | 0.23 (0.03-1.80) | 0.89 (0.18-4.43) |
| Prior therapy, ≥3 vs <3) | 1.73 (0.36-8.21) | 1.45 (0.65-3.24) | 0.88 (0.43-1.82) | 2.96 (1.02-9.78) | 1.16 (0.31-4.38) | N/A* |
| History of SCT, yes vs no | 0.66 (0.15-3.00) | 1.12 (0.52-2.42) | 1.38 (0.67-2.84) | 1.11 (0.43-2.90) | 0.61 (0.13-2.82) | 1.74 (0.43-7.29) |
| Baseline LDH, normal vs high | 0.65 (0.19-2.24) | 0.53 (0.26-1.07) | 0.55 (0.28-1.08) | 1.13 (0.42-2.41) | 0.19 (0.04-0.89) | 0.12 (0.01-0.99) |
| Performance status, ≥2 vs 0-1 | 0.42 (0.05-3.32) | 2.41 (1.09-5.35) | 0.94 (0.38-2.30) | 1.88 (0.53-6.71) | 2.82 (0.80-10.0) | 1.46 (0.28-7.54) |
| Bridging therapy before CAR T cell, yes vs no | 2.56 (0.54-12.0) | 1.24 (0.61-2.50) | 1.29 (0.62-2.68) | 0.49 (0.20-1.17) | 6.40 (0.82-50.1) | 4.40 (0.54-35.8) |
| Time from leukapheresis to CAR T-cell infusion, d | 0.88 (0.79-0.99) | 0.99 (0.96-1.02) | 0.99 (0.96-1.02) | 1.00 (0.97-1.04) | 0.97 (0.91-1.03) | 0.95 (0.87-1.03) |
| CRS, yes vs no | 2.64 (0.72-9.75) | 2.25 (1.06-4.75) | 1.71 (0.87-3.35) | 1.49 (0.59-3.75) | 22.48 (2.83-178.32) | 8.04 (1.37-47.05) |
| . | HR (95% CI) . | |||||
|---|---|---|---|---|---|---|
| Cardiovascular . | Metabolic . | Hematologic . | Infection with source . | Neurologic . | Pulmonary . | |
| Age, ≥60 vs <60 y | 1.39 (0.37-5.24) | 1.43 (0.68-3.02) | 0.73 (0.37-1.45) | 0.78 (0.32-1.94) | 2.88 (0.62-13.3) | 1.75 (0.35-8.70) |
| CAR T-cell product, tisagenlecleucel vs axicabtagene ciloleucel | N/A* | 0.62 (0.27-1.44) | 0.46 (0.19-1.13) | 0.96 (0.35-2.64) | 0.23 (0.03-1.80) | 0.89 (0.18-4.43) |
| Prior therapy, ≥3 vs <3) | 1.73 (0.36-8.21) | 1.45 (0.65-3.24) | 0.88 (0.43-1.82) | 2.96 (1.02-9.78) | 1.16 (0.31-4.38) | N/A* |
| History of SCT, yes vs no | 0.66 (0.15-3.00) | 1.12 (0.52-2.42) | 1.38 (0.67-2.84) | 1.11 (0.43-2.90) | 0.61 (0.13-2.82) | 1.74 (0.43-7.29) |
| Baseline LDH, normal vs high | 0.65 (0.19-2.24) | 0.53 (0.26-1.07) | 0.55 (0.28-1.08) | 1.13 (0.42-2.41) | 0.19 (0.04-0.89) | 0.12 (0.01-0.99) |
| Performance status, ≥2 vs 0-1 | 0.42 (0.05-3.32) | 2.41 (1.09-5.35) | 0.94 (0.38-2.30) | 1.88 (0.53-6.71) | 2.82 (0.80-10.0) | 1.46 (0.28-7.54) |
| Bridging therapy before CAR T cell, yes vs no | 2.56 (0.54-12.0) | 1.24 (0.61-2.50) | 1.29 (0.62-2.68) | 0.49 (0.20-1.17) | 6.40 (0.82-50.1) | 4.40 (0.54-35.8) |
| Time from leukapheresis to CAR T-cell infusion, d | 0.88 (0.79-0.99) | 0.99 (0.96-1.02) | 0.99 (0.96-1.02) | 1.00 (0.97-1.04) | 0.97 (0.91-1.03) | 0.95 (0.87-1.03) |
| CRS, yes vs no | 2.64 (0.72-9.75) | 2.25 (1.06-4.75) | 1.71 (0.87-3.35) | 1.49 (0.59-3.75) | 22.48 (2.83-178.32) | 8.04 (1.37-47.05) |
SCT, stem cell transplantation.
N/A, not applicable because no event occurred in either subgroup, so HR could not be calculated for that comparison.